Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs

Inflammation Research

Volumn 46, Issue 4, 1997, Pages 147-153

  Kagoshima, M ^a   Tomomatsu, N ^a   Iwahisa, Y ^a   Yamaguchi, S ^a   Matsuura, M ^a   Kawakami, Y ^a   Terasawa, M ^a  

^a Research Laboratories   (Japan)

Author keywords

Accumulation of eosinophil; Airway hyperresponsiveness; Asthma; PAF; Y 24180

Indexed keywords

ANTIASTHMATIC AGENT; ISRAPAFANT; OZAGREL; PRANLUKAST; SERATRODAST; THEOPHYLLINE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHIL; GUINEA PIG; LUNG LAVAGE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION;

EID: 0030890703     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050539     Document Type: Article

References (52)

1. Booij-Noord H, Orie, NGM, de Vries K. Immediate and late bronchial obstructive reactions to inhalation of house dust and protective effects of disodium cromoglycate and predonisolone. J Allergy Clin Immunol 1971;48:344-54.
2. Cartier A, Thomson NC, Frith PA, Roberts R, Hargreave FE. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway calibre. J Allergy Clin Immunol 1982;70:170-7.
3. De Monchy JGR, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 1985; 131:373-6.
4. Dolovich J, Hargreave FE, Jordana M, Denburg J. Late-phase airway reaction and inflammation. J Allergy Clin Immunol 1989;83:521-4.
5. Vargaftig BB, Lefort J, Chignard M, Benveniste J. Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of porstaglandins derivatives. Eur J Pharmacol 1980;65:185-92.
6. Halonen M, Palmer JD, Lohman IC, McManus LM, Pinekard RN. Respiratory and circulatory alterations induced by acetylglyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit. Am Rev Respir Dis 1980;122:915-24.
7. Cuss FM, Dixon CMS, Barnes PJ. Effects of inhaled platelet-activating factor on pulmonary function and bronchial responsiveness in man. Lancet II 1986;189-92.
8. Arima M, Yukawa T, Terashi Y, Sagara-H, Makino S. Platelet activating factor (PAF)-induced late asthmatic response in sensitized but not in non-sensitized guinea pigs. Jpn J Allergol 1992;41:607-14.
9. Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 1986;78:1701-6.
10. Henocq E, Vargaftig BB. Accumulation of eosinophils in response to intracutaneous PAF-acether and allergen in man. Lancet I 1986;1378-9.
11. Horie S, Kita H. CD11b/CD18(Mac-1) is required for degranulation of human eosinophils induced by human recombinant granulocyte-macrophage colony-stimulating factor and platelet-activating factor. J Immunol 1994;152:5457-67.
12. Chung KF, Aizawa H, Leikauf GD, Ueki IF, Evans TW, Nadel JA. Airway hyperresponsiveness induced by platelet activating factor: role of thromboxane generation. J Pharmacol Exp Ther 1986; 236:580-4.
13. Anderson GP, White HL, Fennessy MR. Increased airways responsiveness to histamine induced by platelet activating factor in the guinea pigs: possible role of lipoxygenase metabolites. Agents Actions 1988;24:1-7.
14. Morooka S, Uchida M, Imanishi N. Platelet activating factor (PAF) plays an important role in the immediate asthmatic response in guinea pig by augmenting the response to histamine. Br J Pharmacol 1992;105:756-62.
15. Terasawa M, Aratani H, Setoguchi M, Tahara T. Pharmacological actions of Y-24180: I. A potent and specific antagonist of platelet activating factor. Prostaglandins 1990;40:553-69.
16. Takehara S, Mikashima H, Muramoto Y, Terasawa M, Setoguchi M, Tahara T. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors. Prostaglandins 1990;40:571-83.
17. Inoue H, Aratani H, Takishima T, Kagoshima M, Iwahisa Y, Terasawa M. Effect of a potent PAF antagonist, Y-24180, on an allergen-induced late asthmatic response in guinea-pigs. J Lipid Med 1992;5:173-6.
18. Fujimura M, Sakamoto S, Matsuda T. Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma. Chest 1990;98:656-60.
19. Nambu F, Murakata S, Shiraji T, Omawari N, Sawada M, Okegawa T, et al. OKY-046 inhibits anaphylactic bronchoconstriction and reduce histamine level in bronchoalveolar lavage fluid in sensitized guinea pigs. Prostaglandins 1990;39:623-37.
20. 4 antagonist: ONO-1078, on adult bronchial asthma in multi-center comparative double blind clinical study with azelastine hydrochloride. J Clin Ther Med 1993;9:71-107.
21. Nakagawa N, Obata T, Kobayashi T, Okada Y, Nambu F, Terawaki T, et al. Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthma. Eur J Pharmacol 1993;235:211-9.
22. 2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma. J Allergy Clin Immunol 1991;87:23-7.
23. Matsumoto T, Ashida Y, Tsukuda R. Pharmacological modulation of immediate and late airway response and leukocyte infiltration in guinea pig. J Pharmacol Exp Ther 1994;269:1236-44.
24. Iwama T, Komatsu N, Shikada K, Tanaka S. Reversing effect of anti-asthmatic drugs on bronchoconstriction induced by antigen challenge and histamine in anesthetized guinea pigs. Jpn J Pharmacol 1992;58:19-25.
25. Pauwels R, Van Renterghem D, Van Der Straeten M, Johannesson N, Persson CGA. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol 1985;76:583-90.
26. Arimura A, Asanuma F, Matsumoto Y, Kurosawa A, Jyoyama H, Nagai H. Effect of the selective thromboxane A2 receptor antagonist, S-1452, on antigen-induced sustained bronchial hyperresponsiveness. Eur J Pharmacol 1994;260:201-9.
27. Konzett H, Rössler R. Versuchsanordnung zu untersuchungen an der bronchialmuskulatur. Naunyn Schmiedebergs Arch Exp Pathol Pharmacol 1940;195:71-4.
28. 2 synthetase inhibitor, on antigen-induced airway hyperresponsiveness in guinea pigs. Int Arch Allergy Appl Immunol 1991;96:238-43.
29. Terashi Y, Yukawa T, Fukuda T, Makino S. Late phase response in the guinea pig airway caliber following inhaled antigen exposure I. Comparative study of passively and actively sensitized models. Jpn J Allergol 1988;37:980-91.
30. Mead J. Control of respiratory frequency. J Appl Physiol 1960;15:325-36.
31. 4 and platelet-activating factor-acether antagonists on allergic and arachidonic acid-induced reactions in guinea pig airways. Can J Physiol Pharmacol 1989;67:483-90.
32. 4 and PAF receptor antagonists in decreasing antigen-induced airway microvascular leakage. Adv Prostaglandin Thromboxane Leukotr Res 1995;23:271-3.
33. Hargreave FE, Ryan G, Thomson NC, O'Byrne PM, Latimer K, Juniper EF, et al. Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol 1981;68:347-55.
34. 2 synthetase inhibitor (OKY-046·HCl) on airway hyperresponsiveness in guinea pigs. Eur J Pharmacol 1990; 184:87-95.
35. Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyper-responsiveness in patients with asthma. Respir Med 1993;87:133-8.
36. 4 potentiates histamine-induced bronchoconstruction in guinea pigs. Agents Actions 1984;15:146-52.
37. 2. Prostagl Leukotr Ess Fatty Acids 1988;33:185-9.
38. Havill AM, Van Valen RG, Handley DA: Prevention of non-specific airway hyperreactivity after allergen challenge in guinea pigs by the PAF receptor antagonist SDZ 64-412. Br J Pharmacol 1990;99:396-400.
39. Hozawa S, Haruta Y, Ishioka S, Yamakido M. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am J Respir Crit Care Med 1995;152:1198-202.
40. O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1987;136:740-51.
41. Yamada N, Kadowaki S, Umezu K. Development of an animal model of late asthmatic response in guinea pigs and effects of Anti-asthmatic drugs. Prostaglandins 1992;43:507-21.
42. Guinot P, Brambilla C, Duchier J, Braquet P, Bonvoisin B, Cournot A. Effect of BN 52063, a specific PAF-acether antagonist, on bronchial provocation test to allergens in asthmatic patients a preliminary study. Prostaglandins 1987;34:723-31.
43. Perruchoud AP, Yerger L, Abraham WM. Differential effects of aminophylline on the early and late antigen-induced bronchial obstruction in allergic sheep. Respiration 1984;46:44.
44. 4 antagonist (ONO-1078) on immediate and late asthmatic response induced by antigen inhalation. J Clin Ther Med 1993;9:221-4.
45. Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991;87:893-910.
46. Wardlaw AJ, Kay AB. The role of eosinophil in the pathogenesis of asthma. Allergy 1987;42:321-55.
47. Motojima S, Frigas E, Loegering DA, Gleich GJ. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis 1989;139:801-5.
48. Frigas E, Gleich GJ. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986;77:527-37.
49. Kita H, Abu-Ghazaleh RI, Gleich GJ, Abraham RT. Regulation of Ig-induced eosinophil degranulation by adenosine 3′, 5′-cyclic monophosphate. J Immunol 1991;146:2712-8.
50. Van Oosterhout AJM, Fattah D, Van Ark I, Hofman G, Buckley TL, Nijkamp FP. Eosinophil infiltration precedes development of airway hyperreactivity and mucosal exudation after intranasal administration of interleukin-5 to mice. J Allergy Clin Immunol 1995;96:105-12.
51. Kameyoshi Y, Schroder JM, Christophers E, Yamamoto S. Identification of the cytokine RANTES released from platelets as an eosinophil chemotactic factor. Int Arch Allergy Immunol. 1994;104:49-51.
52. Nakagawa N, Obata T, Kobayashi T, Okada Y, Nambu F, Terawaki T, et al. In vivo pharmacological profile of ONO-1078: a potent, selective and orally active peptide leukotriene (LT) antagonist. Jpn J Pharmacol 1992;60:217-25.